So supporting the hypothesis that cPLA2α could represent a specific therapeutic target for a clinically challenging subset of breast cancer patients with highly invasive, endocrine resistant tumours of the HER2-positive or triple-negative subtype. Here, ERBB2 is linked to breast carcinoma.